You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM

Authors

  • Markella Zannikou Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Joseph T Duffy Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Rebecca N Levine Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Maggie Seblani Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USADivision of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USADepartment of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Qianli Liu Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Aaron Presser Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Victor A Arrieta Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Christopher J Chen Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Adam M Sonabend Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Craig M Horbinski Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Catalina Lee-Chang Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Jason Miska Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Maciej S Lesniak Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles
  • Stephen Gottschalk Department of Bone Marrow Transplant and Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee, USA PubMed articlesGoogle scholar articles
  • Irina V Balyasnikova Department of Neurological Surgery, Northwestern University, Chicago, Illinois, USANorthwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articlesGoogle scholar articles

Citation

Zannikou M, Duffy JT, Levine RN, et al
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
Journal for ImmunoTherapy of Cancer 2023;11:e006239. doi: 10.1136/jitc-2022-006239
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.